From Virtual Care to Virtual Research

October, 18, 2021 | 2 Comments


  1. Success Story: GSK – A breakthrough in the virtual world with Dreamcast

    GSK experiments with digital biomarkers to optimize clinical trials GlaxoSmithKline (GSK) is experimenting with wearable mobile health devices linked to cloud services in clinical trials as part of a bid to better engage with patients, speed up the process, and capture data more effectively. GSK is working with Medidata, Vital Connect, and ActiGraph to test six healthy human subjects and see how the wearable sensors perform. The joint initiative assessed the capabilities of mobile health sensors tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs.

    Digital Reimagination™ of Clinical Trials

  2. Big Harma have also realised they can use digital exclusion to secretly exclude those most at risk of having side effects from their drugs and vaccines. All they have to do is collect data using a digital diary and have that as part of the study protocol.

    Of course, to use a digital diary, you must be able to use a digital device like a smartphone, tablet or computer. And you have to be able to remember your login and password details, recall that you need to fill out the diary every day, and remember that you have side effects. Which is fine is you’ve ever owned or used a digital device and you have a good memory.

    If you take the recent COVID vaccine trials as an example, you’ll already know that the average age of death is well over 80 years old. Which means that your target demographic has at least a 1 in 6 risk of already being diagnosed with dementia (your chance is about 50/50 if you’re 90 years old). They have an average age of “retired in the last millennium long before the first iPhone was invented.” They’re also most likely to have been living on a state pension which doesn’t leave them enough money to heat their homes or buy nutritious food, let alone own a smartphone. More recent research confirms that the top comorbidity in those who died from COVID is indeed dementia.

    The drug companies are very aware that dementia is an insurmountable obstacle to using a digital diary. They also know that any sort of inflammation or toxicity effect can aggravate confusion in a person with dementia or even mild cognitive impairment and that can make them unable to use a digital diary. And they know that many of these people live in care homes and that during lockdown they weren’t allowed visitors. So there was nobody to assist them in using digital diaries even if they had wanted to.

    Many people have written about how few high risk elders were included in the vaccine trials and how the trials focused on healthy younger people. It’s pretty clear how they managed to do this. And it’s pretty clear why they chose to do this. They obviously wanted to exclude those most at risk of side effects. Because if they had been confident that their products worked to reduce death, they would have mostly focused on people over 80 years of age with multiple comorbidities.

Leave a Reply